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CLINICAL STUDIES MYOCARDIAL INFARCTION 
Circadian Variations of Onset of Acute Myocardial Infarction and 
Efficacy of ‘I’hrombolytic Therapy 
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Objectives. The present study investigated whether the onset of 
acute myocardiai infarction and resistance to thromboiysis have 
slmlbxr dreadian variations. 
Background. Circadian variations of the onset of acute myocar- 
dial infarction and resistance to thromboiysis in the early morn- 
ing have been reported. Some studies have also reported a 
secondary peak inctdence in late evening; however, it is not hnowu 
whether the resistance :o thromboiysis has a similar circadian 
variation in these patients. 
Rfailrodc. Six hundred eight Japanese patients with an acute 
myocardiai infarction were the subjects of the study. Two hundred 
forty-four of the 608 patients were treated with thromboiysis 
within 12 h of the onset of symptoms. One hundred thirteen 
patients received uroldnase, and 131 patients received tissue-type 
piasminogen activator (t-PA) over 6ti min. Patency of the infarct- 
related artery, the primary end point of the study, was evaluated 
-- 
at 60 min affer the initiation of thromboiytir t!terapy, and 
Thrombolysis in Myocardiai Infarction (TIMI) grade 0,l or 2 was 
dellned as resistaut to thromboiysis. 
&s&. The onset of acute myocardiai infarction and resis- 
tance to thromboiysis showed circadian varlatlons with early 
morning and late evening peaks (p < 0.081 and p < 0.05, 
respectively). These circadian patterns showed similar distribu- 
tions as evaluated with Spearman’s method (r = 0.70, p < 0.09, 
although resistance to thrombolysis showed a phase difference of 
about 2 h earlier than the infarction iocidence. The circadian 
variation of the resistance to thromboiysis was independent of the 
types of thromboiytic agents (umhinase or t-PA). 
Couck.won.v. These findings suggest that adjustment of treat- 
ment based on the time of the onset of symptoms may be 
warranted for the patients with acute myocardiii infarction. 
(JAm Gnl Car&d 1996;27:774-8) 
The frcqucncy of onset of acute myocardial infarction has been 
reported to have a circadian variation. A majority of large scale 
reports (l-4) have shown a peak incidence between 6 .+M and 
noon. although a secondary peak incidence in the late evening 
has also been reported in some studies (5-i I). These differ- 
ences could result in some instances from small study groups, 
from different customs regarding meals or work habits of 
various countries, or from differences in other modifying 
patient factors. The morning increase in ischemia is related to 
an imbalance hetween myocardiai oxygen supply and demand 
reflecting sympathetic/vagd) balance (12-U) increased plate- 
let aggregability (16,17) and reduced plasma fibrinoiytic activ- 
ity in the morning (18-24). The reasons for the late evening 
peak incidence are less clear. 
Circadian fluctuation has also been reported in the egicacy 
of intravenous tissue-type plasminogcn activator (t-PA) in 
patienls with acute myocdrdial infarction, with resistance to 
rhrombolysis during the morning hours (25,26). This morning 
--- 
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resistance to thrombolysis was speculated to be the result of 
elevations of plasminogen activator inhibitor-l in the morning 
(25-27). A morning increase in resistance to thrombolysis was 
also shown in treatment with intracoronary urokinase (28), 
suggesting that this circadian pattern may be independent of 
the type of thromboiytic agent. However, it is not known 
whether the resistance to thromboiysis is also present in the 
late evening in patients who showed a secondary peak inct- 
dence in the late evening. 
The purpose of the present study was to investigate retro- 
spectively whether the onset of acute myocardiai infarction and 
the resistance to thrombolysis had similar circadian variations. 
Methods 
Study patients. We studied 6u8 Japanese patients with 
acute myocardial infarction, who were admitted to the Osaka 
Mishima Critical Care Medical Center between November 
1985 and June 1995. Acute myocardial infarction was diag- 
nosed by the presence of chest pain suggestive of myocardial 
ischemid lasting more than 30 min and at least 0.1 mV ST 
segment elevation in at least two contiguous leads despite 
treatment with nitrates. The diagnosis was confirmed by the 
elevation of cardiac enzymes. The time of onset of symptoms 
was ascertained as precisely as possible. 
Two hundred forty-four patients among these 608 patients 
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were treated with thrombolflic agents within 12 h of the onset 
of acute myocardial infarction, after the evaluation of the 
infarct-related artery by coronary angiography. One hundred 
thirteen patients were treated with urokinase, and 131 patients 
were treated with t-PA. Exclusion criteria were cardiogenic 
shock (systolic blood pressure GO mm Hg unresponsive to 
fluids and vasopressors), uncontrolled hypertension (>180/ 
110 mm Hg), prior cerebrovascular accident and evidence of 
recent or active bleeding. 
Study protocol. Patients with acute myocardial infarction 
who were four,d to satisfy eligibility criteria for the thrombu- 
lytic therapy were transferred to the cardiac catheterization 
laboratory, where coronary angiography was performed to 
evaluate the infarct-related artery. Arterial access was ob- 
tained through the femoral route. Heparin (5,000 U) was 
administered immediately after access was established, and 
patients received oral aspirin (81 mg). When the infarct- 
related artery remained occluded after intracoronary adminis- 
tration of 200 pg of nitroglycerin or 2 mg of isosorbide 
dinitrate, patients received one of the following thrombolytic 
agents according to the attending physician’s decision: 1) 
intracoronary urokinase, a total of 240,000 to 1,200,0@0 IU, 
over 60 min; 2) intravenous t-PA (Aheplase), a total of 0.50 to 
0.75 mg/kg body weight (290,000 to 435,000 IU/kg), over 
60 min with 10% given as a bolus. Patency of the infarct- 
related artery, the primary end point of the study, was evaiu- 
ated at 60 mitt after the initiation of thrombolytic therapy. The 
flow pattern of the infarct-related artery was graded according 
to the Thrombolysis in Myocardial Infarction (TIMI) classifi- 
cation (29,30), and TIM1 0, 1 or 2 was defined as resistant to 
thronrbolytic therapy. All cineangiograms were evaluated by 
cardiologists who had no knowledge of patient characteristics. 
The protocol for the thromboiytic Lxapy was approved by 
the Institutional Review Board of the Osaka Mishima Criti- 
cal Care Medical Center, and written informed consent was 
obtained from all patients or their family members, or both, 
after the purpose of therapy was fully explained. 
Statistical analysis. Comparisons between total cohort and 
patients treated with thrombolytic agents were made usmg the 
unpaired Student I test to compare interval scales and using the 
chi-square test to compare the nominal data. The circadian 
distributions of the frequency of onset of acute myocardial 
infarction in the overall cohort and resistance to thrombolysis 
in patients treated with thrombolytic agents were tested for 
uniformity by a chi-square test for goodness of fit (31). 
Uniformity was evaluated by 2-h intervals of the day. The 
similarity of the circadian variations between the onset of acute 
myocardial infarction and the resistance to thrombolysis was 
evaluated using a Spearman’s rank correlation analysis (32). 
One-way analysis of variance (ANOVA) was used to evaluate 
differences in doses of urokinase or t-PA and differences in 
time to thrombolytic therapy at different times within 24 h. 
When the result was significant, Bonferroni’s multiple compar- 
ison test was performed; p < 0.05 was considered signit+:,,. 
Table 1. Clinical Characteristics for Tolal Cohort and Patients 
With Thromlmlysis 
Total Cohort 
(0 = 608) 
Patient9 With 
Tbromboiyais 
(a = 244) 
Age (yr) (mean i SD) 
Men/women (no.) 
Location of AM1 
Anterior 
Inferior 
Lateral 
History of angina 
Itistory 01 AMI 
Coronary risk factors 
Smoking 
Hypertension 
DM 
Hyperlipidemia 
61~11 
465/1‘!3 
329 (54.1) 
2.35 (38.7) 
44 (7.2) 
147 (24 2) 
il(r ( iO.9) 
324 (53.3) 
269 (44.2) 
109(17.9) 
78(12.8) 
59e10 
I!%/46 
139 (57.0) 
95 (.%.9) 
lO(4.1) 
52 (21.3) 
23 (9.4) 
lSO(61.5) 
95 (3119) 
40 (16.4) 
40 ( 16.4) 
p = NS for all Eompatiwns. Dalr presented are number (%) of patients, 
unles otherwise indicated. AMI = acute mywardial infarction; DM = diabetes 
mellitus. 
Results 
The patient characteristics in the total cohort and in 
patients treated with thrombolytic therapy were well matched, 
as shown in Table 1. The number of women was slightly lower 
among patients treated with thromboolysis than in the tctd 
group, although the difference was not StatisticaIIy signilicant. 
The circadian distribution of the onset of acute myocardial 
infarction in the overall cohort and the resistance to throm- 
bolysis in the patients treated with thrombolytic agents are 
shown in Figure 1. According to the statistical test of unifor- 
mity, the circadian distribution of the onset of acute myocar- 
dial infarction and the circadian distribution of the resistance 
to thrombolysis differed signilicantly from random with early 
morning and late evening peaks (p < 0.001 and p < 0.05, 
respectively), as shown in Figure 1. The patients treated with 
thrombolysis showed the same circadian viability in incidence 
of myocardial infarction as the total cohort did. 
The circadian patterns of the onset of acute myocardial 
infarction and the resistance to thrombolysis showed similar 
distributions as evaluated with a Spearmans rank correlation 
analysis (r = 0.70, p < O.OS), although the resistance to 
thrombolysis showed a phase difference of about 2 h earlier 
than infarction incidence as shown in Figure 1. There was no 
difference in the circadian variatiop of the resistance to 
thrombolysis between patients treated with umkinase and 
patients treated with t-PA, as shown in Figure 2. There were no 
differences in doses of either urokinase or t-PA at the various 
times of day, as shown in Figures 3 and 4. The time from the 
onset of symptoms to thromb&tic therapy was longer at 2 AM 
to 4 AM than at other times of day, and there was no relation 
either to dosing of thrombolytic therapy or to thrombolytic 
efficacy, as shown in Figure 5. 
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Figure 1. Temporal distribution of onsel of acute myocardial infarc- 
tion and resi\tuncc to tlxomholysia showei @Clicanr circadian vari- 
ations with e;uly morning and late evening peaks (p < 0.001 and p i 
0.115. respectively). These circadian variations were similar (r = 0.70, 
p < O.OS), although resistance to thrombolysis showed a phase -2 h 
earlier than the infarction incidence. Patients treated with thromhol- 
ysis showed the same circadian viability in incidence of myocardial 
infarction as did the total cohort. AMI = acute myocardial infarction: 
t-PA = tissue-type plasminogen activator; UK = urokinasc. 
Discussion 
The present study demonstrated that the onset of acute 
myocardiai infarction and the resistance to thrombolysis have 
similar circadian variations with early morning and late 
evening peaks, although the resistance to thrombolysls showed 
a phase difference of about 2 h earlier than infarction inci- 
dence. This circadian variation of the resistance to thrombol- 
ysis was independent of the types of thrombolytic agents 
(urokinase or @A). 
Figure 2. circadian varialions of resistance IO Ihromholysia in pelients 
treated with urokinase (UK) ;md those treated with tksue-type plas- 
minogrn activalor (l-PA). ReGtance 10 thromholysis showed similar 
circadian variations in the two groups. AMI = acute myocardial 
infarction. Data are expressed as mean value % SE 
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Fit+tre 3. Doses of urotinaac used at diffcrcnt times of 0~ day showed 
no significant variation. Dala are expressed as mean value + SE. 
Circadian variation of onset of acute myocardial infarction. 
The onset of acute myocardial infarction has been reported to 
have circadian variations. A majority of large scale reports 
(l-4) have shown a peak incidence between 6 AM and noon, 
although a secondary peak incidence in the late evening has 
also been reported in some studies (5-11). In the present 
study, the onset of acute myocardial infarction had a circadian 
variation with early morning and late evening peaks, which was 
consistent with the reports of others (5-11). These differences 
could in some instances reflect the small study cohort, different 
customs regarding meals or work habits in reported coun!ries, 
or differences in various other patient factors. The morning 
increase in sympathetic activity may cause vasoconstriction and 
may lead to plaque rupture in atherosclerotic coronary arteries 
in combination with mechanical factors such as elevated blood 
pressure (11-15). The increased platelet aggregability (16.17) 
Figure 4. fb:s of tissue-type plasminogcn activator (t-PA) used at 
diffcrcnt times of the day showed no significant variation. Data are 
expressed as mean value f SE. 
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Figure 5. Tim: from onset of symptoms to thrombolytic therapy was 
longer at 2 to4 AM than at other times of the day (‘p < 0.05). and there 
was no relatio, IO either dosing of thrombolytic therapy or tlmmtw- 
lytic efficacy. L’Jta are expressed as mean value + SE. 
and reduced plasma fibrinotytic activity in the morning (18-24) 
may facilitate or accelerate thrombus formation. The reasons 
for the late evening peak incidence are less clear. It was 
reported that pcticnts >70 years of age, smokers, diabetic 
patients, those receiving beta-blockers at the time of symptom 
onset and women had a secondary peak incidence in the late 
evening (9). In the present study, >50% of the study popula- 
tion were smokers, which may be related to a second peak 
incidence in the late evening. Although increased platelet 
aggregability, reduced plasma fibrinolytic activity or increased 
piasminogen activator inhibitor-l, or both, may play important 
roles for the genesis of the onset of acute myocardial infarc- 
tion, we did not evaluate these factors; therefore, the exact 
mechanism of the circadian variation of the onset of acute 
myocardial infarction was not clearly elucidated in the present 
study. 
Circadiac variation of resistance to thrombolysis. Circa- 
dian fluctuation with a morning increase in the resistance to 
thrombolysis by intravenous t-PA (25,26) and intraco, zrlary 
urokirase (28) has been reported. In the present .udy, the 
resistance to thrombolysis showed a circadian variation similar 
to that of the onset of acute myocardial infarction, with early 
morning and late evening peaks, with a phase -2 h earlier than 
that of infarction incidence. This circadian pattern of the 
resistance to thrombolysis was independent of the types of 
thrombolytic agents (urokinase or t-PA) in the present study. 
The highest doses of iniracoronary urokinase were given 
between 6 and 8 AM, which was expected because intracoronary 
urokinase was given for occluded vessels, and more resistant 
occlusions received more urokinase. Although dosing of 
thrombolytic therapy was not statistically different at any 
particular time of day, the dose of t-PA was slightly low& 
during the 6 to 8 AM and 8 to 10 AM time periods than at other 
times of the day, which could influence the resistance to t-PA 
during these hours. However, dosing of t-PA did not affect the 
later peak in resistance to thrombolysis. It was reported that 
there was a greater patency with a shorter time to thrombolytic 
therapy (25); however, the resistance to thrombolysis in the 
early morning and the late evening was not caused by the 
longer time to thrombolytic therapy after symptom onset 
therefore, the time to thrombolytic therapy was not found to 
play an important role in the circadian variation of the 
resistance to thrombolysis in the present study. 
The morning resistance to thrombolysis was reported to be 
associated with elevation of plasminogen acti,lator inhibitor-l 
in the morning (25-27). The reasons for the late evening 
resislance to thrombolysis are not clear. The plasminogen 
activator inhibilor-l was not reported to be increased in the 
late evening (19 -24). The large number of smokers in the 
present study may be related to the observed late evening 
resistance to thrombolysis. The same factors that may affect 
the onset of acute myocardial infarction may also dffect the 
resistance to thrombolysis; however, the exact mechanism of a 
circadian variation of the resistance to thrombolysis was not 
clearly elucidated in the present study. 
Patency of the infarct-retat- artery was -valuated at 
60 min after the initiation of thrombolytic therapy instead of at 
90 min because thromholytic agents were delivered over 
Cfl min, which might influence the patency rate in the present 
study. However, overall Mmin patency rate in the patients 
treated with thrombolytic therapy was 54.1% in the present 
SW& which was compatible with the 90-min patency rates of 
other reports using the same definition of the patency as the 
present study (25). 
Clinical implications. A number of potent& therapeutic 
implications based on the time of the onset of symptoms can be 
presented, each of which would require further investigation. 
The dose CJ thrombolytic agents should be adjusted on the 
basis of time of day; however, a higher dose of thrombolytic 
agents might increase the risk of side effects such as intrace- 
rebral hemorrhage. Thrombolytic agents resistant to plasmin- 
ogen activator inhibitor-l and adjunct pharmacologic agents, 
including potent anticoagulants or antiplatelet agents, might 
improve the resistance to thrombolysis. Mechanical revascn- 
larization such as a direct angioplasty might be a better option 
for treatment in the early morning and late evening. 
Conclusions. The onset of acute myocardiai infarction and 
the resistance to thrombolysis had similar circadian variations 
with early morning and late evening peaks, although the 
resistance to thrombolysis preceded the onset of acute myo- 
cardial infarction. The circadian variation of the resistance to 
thrombolysis was indepndent of the type of thrombolytic 
agent (urokinase or t-PA). These findings suggest that adjust- 
ment of the treafaent based on the time of onset of symptoms 
may be warranted for the patients with acute mvocardial 
infarction. 
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